The U.S. Clinical Trials Landscape Is Changing. Which Opportunities Should Pharma Leaders Watch?

The United States remains one of the world's most important destinations for clinical research. Pharmaceutical companies, biotechnology developers, medical device manufacturers and contract research organisations rely on its research infrastructure to develop and evaluate new treatments.

However, clinical trial success depends on more than the scientific potential of a drug candidate. Patient recruitment, site activation, regulatory processes, trial costs and data quality can influence development timelines and commercial outcomes.

Recent initiatives from the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS) and National Institutes of Health (NIH) indicate growing attention to research efficiency, participant access and modern trial infrastructure.

For pharmaceutical leaders, these developments create opportunities to reassess trial locations, CRO partnerships, patient recruitment strategies and clinical research technology investments.

Source: https://www.towardshealthcare.com/insights/us-clinical-trials-market-sizing 

U.S. Clinical Trials Industry Snapshot

The United States has a substantial clinical research ecosystem supported by pharmaceutical sponsors, academic medical centres, hospitals, independent research sites, CROs and government-funded research programmes.

Two indicators demonstrate the scale of this activity:

• 208,615 U.S. clinical trial registrations: WHO data recorded this total from 1999 through June 2026, placing the United States first by country in the dataset.

• 8.2 million research participants: NIH-supported clinical research enrolled approximately 8.2 million participants at U.S. sites in FY2025. This figure represents NIH-supported research and should not be interpreted as total U.S. clinical trial enrolment.

These figures reflect different aspects of the research ecosystem. Trial registrations capture registered studies, while NIH participant enrolment reflects research supported through NIH programmes. 

The scale creates demand for specialised clinical operations, research infrastructure, patient recruitment services, data platforms and regulatory expertise.

Key Clinical Trial Segments

1. Phase I–IV pharmaceutical and biologic trials

Clinical development progresses through different phases, each addressing distinct research questions.

• Phase I evaluates initial safety, tolerability and pharmacokinetics.

• Phase II investigates preliminary efficacy, dose selection and additional safety information.

• Phase III evaluates efficacy and safety in larger patient populations.

• Phase IV generates additional evidence after regulatory approval.

Sponsors must select suitable sites, investigators and patient populations for each development stage. Oncology, immunology, metabolic diseases and central nervous system disorders remain important areas of clinical development.

2. Oncology, rare disease and cell and gene therapy trials

Specialised trials often require experienced investigators, advanced diagnostic capabilities and access to eligible patient populations.

Oncology trials may depend on biomarker testing and molecular profiling. Rare disease studies can face recruitment limitations because eligible patients are geographically dispersed. Cell and gene therapy trials may require specialised manufacturing coordination, treatment centres and long-term patient follow-up.

These requirements create opportunities for specialised research sites, centralised patient identification and advanced clinical operations.

3. Medical device and diagnostic trials

Medical device studies evaluate safety, performance and clinical effectiveness. Depending on the product and regulatory pathway, studies may involve hospitals, specialist clinics and diagnostic centres.

Areas such as surgical robotics, cardiovascular devices, digital health and AI-enabled diagnostics are creating demand for research sites with specialised technical capabilities.

4. Decentralised and real-time clinical trials

Decentralised clinical trials use technologies and operational models that allow selected research activities to take place outside traditional trial sites.

These may include telehealth consultations, remote monitoring, electronic patient-reported outcomes and home-based study visits.

Real-time trial approaches also aim to make relevant clinical data available more efficiently during research. Adoption depends on study design, data quality, regulatory requirements and the suitability of each trial for remote participation.

Government Initiatives Are Changing Clinical Research Priorities

Three U.S. government developments deserve attention from pharmaceutical sponsors, CROs and research institutions.

FDA Real-Time Clinical Trials Initiative

In April 2026, the FDA introduced its Real-Time Clinical Trials initiative to explore approaches that could provide more timely access to clinical trial data and endpoints.

The initiative included proof-of-concept work and a request for information on opportunities and challenges associated with real-time clinical trial approaches.

For sponsors, the development highlights the importance of modern clinical data infrastructure, timely data collection and more efficient trial monitoring.

HHS Operation TrialBlazer

HHS launched Operation TrialBlazer in June 2026 to strengthen U.S. clinical research capacity.

The initiative reflects a broader focus on improving the clinical research environment and supporting more efficient trial operations.

Its progress is relevant to sponsors evaluating U.S. research sites, domestic trial infrastructure and opportunities to collaborate with healthcare institutions.

NIH and NCI Research Priorities

NIH-supported research plays a major role in the U.S. clinical research ecosystem. The National Cancer Institute (NCI) also supports clinical research through cancer research networks, treatment studies and specialised programmes.

Participant representation, recruitment and access to research remain important considerations. Sponsors and research organisations must develop recruitment approaches that reflect the populations affected by the conditions being studied.

The NIH participant enrolment figure of 8.2 million in FY2025 illustrates the scale of its supported research activity.

Which Companies and Organisations Are Shaping the U.S. Clinical Trial Ecosystem?

The U.S. clinical research landscape includes government agencies, global CROs, specialist service providers, research networks and technology companies.

CROs Are Important Partners for Clinical Development

Contract research organisations help pharmaceutical and biotechnology sponsors manage complex clinical development activities.

Their services can include protocol development support, site identification, patient recruitment, trial monitoring, data management, regulatory support and clinical study management.

IQVIA, ICON, Parexel, Medpace and Fortrea operate across different areas of the clinical research services ecosystem.

Sponsors should compare these providers based on therapeutic expertise, geographic coverage, site networks, recruitment performance, technology capabilities and experience managing similar study designs.

Specialised Research Sites Are Becoming More Important

Not every clinical trial requires the same research infrastructure.

A Phase III oncology study may need access to specialist investigators, diagnostic facilities and large patient populations. A rare disease study may require a smaller network of highly specialised centres.

This creates opportunities for independent research sites, academic medical centres and specialised site networks that can offer access to specific patient populations and clinical expertise.

Where Does the U.S. Clinical Trial Industry Face Challenges?

1. Patient recruitment and retention

Recruiting eligible participants remains a major operational challenge. Complex eligibility criteria, limited disease awareness, travel requirements and competition between studies can slow enrolment.

Sponsors need better patient identification, referral networks and communication strategies to improve recruitment and retention.

2. Site activation delays

Before a clinical trial begins at a research site, sponsors and investigators must complete regulatory documentation, contracts, budgets, ethics review and operational preparation.

Delays in these activities can affect trial timelines and increase development costs.

3. Participant representation

Clinical research needs to generate evidence that is relevant to the populations likely to use a treatment.

However, barriers involving geography, healthcare access, language, eligibility requirements and awareness can affect participation. Sponsors must consider these factors when selecting sites and designing recruitment programmes.

4. Complex data management

Modern trials generate data from electronic health records, laboratory systems, wearable devices, imaging, electronic patient-reported outcomes and clinical databases.

Integrating these sources while maintaining data quality, privacy, security and regulatory compliance requires specialised technology and processes.

5. Rising operational complexity

Multicentre studies, international collaboration, complex biologics and personalised treatments can increase coordination requirements. Sponsors must manage multiple stakeholders while maintaining consistent trial procedures and oversight.

Business Opportunities for Clinical Research Companies

The changing research environment creates opportunities for CROs, technology developers, healthcare organisations and specialised service providers.

• AI-enabled patient matching: Platforms that identify potentially eligible participants using structured clinical data and appropriate consent-based processes.

• Decentralised trial infrastructure: Telehealth, remote monitoring, home nursing and digital patient engagement services.

• Specialised research-site networks: Networks focused on oncology, rare diseases, cell and gene therapy, and other complex therapeutic areas.

• Clinical data platforms: Systems that integrate electronic health records, trial databases, laboratory information and remote monitoring data.

• Clinical trial analytics: Tools for evaluating site performance, recruitment timelines, enrolment risks and operational efficiency.

• CRO partnerships: Collaboration between pharmaceutical sponsors, biotechnology developers, specialist CROs and research institutions.

• Regulatory and quality services: Support for clinical trial documentation, compliance, inspection readiness and quality management.

For emerging companies, opportunities may exist in specialised services rather than competing directly with large global CROs. Patient recruitment technology, trial data integration, site support and disease-specific research services can address important operational gaps.

What Should Pharma Leaders and Investors Track?

The number of registered clinical trials alone does not indicate where the strongest commercial opportunities exist. Decision-makers should assess the quality of research infrastructure, sponsor demand and operational performance.

Important evaluation areas include:

1. Therapeutic area activity: Which disease areas have active development programmes and increasing sponsor requirements?

2. Sponsor pipeline activity: Which pharmaceutical and biotechnology companies are advancing candidates into Phase II and Phase III?

3. Research site capabilities: Which hospitals, academic centres and independent sites have relevant therapeutic expertise?

4. CRO positioning: Which service providers have specialised capabilities, strong site networks and relevant geographic coverage?

5. Recruitment performance: Which organisations can identify and enrol eligible participants efficiently?

6. Technology adoption: Which platforms support remote monitoring, patient matching, real-time data and clinical analytics?

7. Regulatory developments: How are new FDA and HHS initiatives affecting trial planning and operations?

A structured assessment of these factors can help sponsors identify suitable partners, prioritise research locations and evaluate investment opportunities.

How Towards Healthcare Supports Clinical Trial Decision-Making

Towards Healthcare supports pharmaceutical companies, biotechnology developers, CROs and healthcare organisations through structured clinical research and competitive intelligence.

Its capabilities can support:

• Complete Master Datasets: Clinical trial activity, sponsor profiles, pipeline information, research organisations and company developments.

• Competitive Quadrants: Comparison of CROs, research service providers and clinical technology companies.

• Customized Dashboards: Tracking trial activity, therapeutic areas, sponsors, research sites and competitive developments.

• Pipeline Intelligence: Monitoring drug and biologic candidates across clinical development stages.

• Buyer Identification: Identifying pharmaceutical sponsors, biotechnology companies, CROs and research institutions.

• GTM Strategy: Assessing therapeutic opportunities, target organisations and potential research partnerships.

The U.S. clinical trials landscape is evolving as sponsors seek faster research operations, broader patient access and more integrated clinical data systems.

For pharmaceutical leaders, the next opportunity is to identify where clinical development demand is increasing, which research partners can deliver specialised capabilities and which technologies can address persistent operational barriers.

Explore U.S. clinical trial intelligence, sponsor benchmarking, research-site opportunities and clinical development insights with Towards Healthcare.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram